Literature DB >> 30928567

Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine.

Jeffrey Ecker1, Alfred Abuhamad1, Washington Hill1, Jennifer Bailit1, Brian T Bateman1, Vincenzo Berghella1, Tiffany Blake-Lamb1, Constance Guille1, Ruth Landau1, Howard Minkoff1, Malavika Prabhu1, Emily Rosenthal1, Mishka Terplan1, Tricia E Wright1, Kimberly A Yonkers1.   

Abstract

Mesh:

Year:  2019        PMID: 30928567     DOI: 10.1016/j.ajog.2019.03.022

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


× No keyword cloud information.
  13 in total

1.  Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis.

Authors:  Ashish Premkumar; William A Grobman; Mishka Terplan; Emily S Miller
Journal:  Obstet Gynecol       Date:  2019-11       Impact factor: 7.661

Review 2.  Targeted drug delivery for maternal and perinatal health: Challenges and opportunities.

Authors:  Anjali Sharma; Nirnath Sah; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2021-08-26       Impact factor: 17.873

3.  "You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.

Authors:  Davida M Schiff; Erin C Work; Serra Muftu; Shayla Partridge; Kathryn Dee L MacMillan; Jessica R Gray; Bettina B Hoeppner; John F Kelly; Shelly F Greenfield; Hendrée E Jones; Timothy E Wilens; Mishka Terplan; Judith Bernstein
Journal:  J Subst Abuse Treat       Date:  2022-03-18

4.  Comprehensive Treatment for Pregnant and/or Parenting Women with Substance Use Disorders and Their Children: A Cross-Cultural Comparison.

Authors:  Hendrée Jones E; Stacey Klaman L; Catherine Leiner; Raquel da Silva Barros; Roberto Canay; Jesica Suarez V; Rocio Suarez Ordoñez M; Kevin O'Grady E
Journal:  J Subst Abus Alcohol       Date:  2021-01-23

5.  Implementing a Learning Collaborative Framework for States Working to Improve Outcomes for Vulnerable Populations: The Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence Syndrome Initiative Learning Community.

Authors:  Charlan D Kroelinger; Donna Addison; Mirelys Rodriguez; Marion E Rice; Meghan T Frey; Hadley R Hickner; Mary Kate Weber; Trish Mueller; Alisa Velonis; Keriann Uesugi; Lisa Romero; Sanaa Akbarali; Natalie Foster; Jean Y Ko; Ellen Pliska; Christine Mackie; Shanna Cox; S Nicole Fehrenbach; Wanda D Barfield
Journal:  J Womens Health (Larchmt)       Date:  2020-03-13       Impact factor: 2.681

6.  Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review.

Authors:  Erica N Onuoha; Jared A Leff; Bruce R Schackman; Kathryn E McCollister; Daniel Polsky; Sean M Murphy
Journal:  Value Health       Date:  2021-05-08       Impact factor: 5.101

Review 7.  Prenatal drug exposure and neurodevelopmental programming of glucocorticoid signalling.

Authors:  Alexis L Franks; Kimberly J Berry; Donald B DeFranco
Journal:  J Neuroendocrinol       Date:  2019-10-02       Impact factor: 3.870

8.  Maternal Substance Use: Consequences, Identification, and Interventions.

Authors:  Grace Chang
Journal:  Alcohol Res       Date:  2020-06-30

9.  Treatment of Opioid Use Disorder in Pregnant Women via Telemedicine: A Nonrandomized Controlled Trial.

Authors:  Constance Guille; Annie N Simpson; Edie Douglas; Lisa Boyars; Kathryn Cristaldi; James McElligott; Donna Johnson; Kathleen Brady
Journal:  JAMA Netw Open       Date:  2020-01-03

10.  Standardized Criteria for Review of Perinatal Suicides and Accidental Drug-Related Deaths.

Authors:  Marcela C Smid; Jewel Maeda; Nicole M Stone; Heidi Sylvester; Laurie Baksh; Michelle P Debbink; Michael W Varner; Torri D Metz
Journal:  Obstet Gynecol       Date:  2020-10       Impact factor: 7.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.